LIVIVO - Search results -

Search results

Result 1 - 10 of total 26

Search options

Article ; Online: Comments On The Treatment Of Resistant Tuberculosis.

2017 Volume 54, Issue 5, Page(s) 297

Title translation	Comentarios al tratamiento de la tuberculosis con resistencia.
MeSH term(s)	Humans ; Tuberculosis ; Tuberculosis, Multidrug-Resistant
Language	Spanish
Publishing date	2017-12-06
Document type	Letter ; Comment
ZDB-ID	733126-5
ISSN	1579-2129 ; 0300-2896
ISSN (online)	1579-2129
ISSN	0300-2896
DOI	10.1016/j.arbres.2017.10.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treatment of pulmonary and extrapulmonary tuberculosis.

Pascual-Pareja, José Francisco / Carrillo-Gómez, Raquel / Hontañón-Antoñana, Victor / Martínez-Prieto, Mónica

Enfermedades infecciosas y microbiologia clinica (English ed.)

2017 Volume 36, Issue 8, Page(s) 507–516

Abstract: The purpose of tuberculosis treatment is twofold: to provide an individual benefit centred on healing the patient with TB, and to provide a collective benefit to the community in which the patient resides. The different treatment regimens for ... ...

Title translation	Tratamiento de la enfermedad tuberculosa pulmonar y extrapulmonar.
Abstract	The purpose of tuberculosis treatment is twofold: to provide an individual benefit centred on healing the patient with TB, and to provide a collective benefit to the community in which the patient resides. The different treatment regimens for tuberculosis sensitive to first-line antituberculosis drugs as well as resistant tuberculosis are examined and the peculiarities in the management of pulmonary and extrapulmonary tuberculosis are discussed.
MeSH term(s)	Antitubercular Agents/therapeutic use ; Humans ; Mycobacterium tuberculosis/drug effects ; Tuberculosis/complications ; Tuberculosis/drug therapy ; Tuberculosis/microbiology ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Pulmonary/drug therapy
Chemical Substances	Antitubercular Agents
Language	Spanish
Publishing date	2017-11-21
Document type	Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimc.2017.10.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Nuevos fármacos antituberculosos en la tuberculosis resistente y multirresistente.

Ramírez Lapausa, Marta / Pascual Pareja, José Francisco / Noguerado Asensio, Arturo

Medicina clinica

2013 Volume 141, Issue 7, Page(s) 306–313

Abstract: Drug-resistant tuberculosis is a globally emerging problem with a rising incidence. According to the WHO in 2008, 17% of strains of Mycobacterium tuberculosis, in untreated cases were resistant to at least one drug and 3.6% were resistant to rifampicin ... ...

Title translation	New tuberculosis drugs in resistant and multiresistant tuberculosis.
Abstract	Drug-resistant tuberculosis is a globally emerging problem with a rising incidence. According to the WHO in 2008, 17% of strains of Mycobacterium tuberculosis, in untreated cases were resistant to at least one drug and 3.6% were resistant to rifampicin and isoniazid, which is called multidrug-resistant tuberculosis. The problem is greater in patients previously treated and in some countries, where rates of multidrug resistance reach 60%. Approximately 5% of multidrug-resistant tuberculosis patients are also resistant to any fluoroquinolone and at least one injectable drug, being called extensively drug-resistant tuberculosis. The treatment of these forms of tuberculosis requires the use of second-line drugs, which causes higher cost, higher toxicity and a longer duration of treatment. There is a need for new compounds with efficacy and safety profiles better than those currently used to treat these forms of tuberculosis. In the last decade different drugs have being reassessed and appeared, which are at different stages of development.
MeSH term(s)	Antitubercular Agents/classification ; Antitubercular Agents/economics ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Clinical Trials as Topic ; Drug Resistance, Multiple, Bacterial ; Drug Therapy, Combination ; Drugs, Investigational/classification ; Drugs, Investigational/economics ; Drugs, Investigational/pharmacology ; Drugs, Investigational/therapeutic use ; Extensively Drug-Resistant Tuberculosis/drug therapy ; Extensively Drug-Resistant Tuberculosis/epidemiology ; Humans ; Mycobacterium tuberculosis/drug effects ; Tuberculosis/drug therapy ; Tuberculosis/epidemiology ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/epidemiology
Chemical Substances	Antitubercular Agents ; Drugs, Investigational
Language	Spanish
Publishing date	2013-10-05
Publishing country	Spain
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1016/j.medcli.2013.01.039
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.

Pascual Pareja, José Francisco / García-Caballero, Rebeca / Soler Rangel, Llanos / Vázquez-Ronda, Miguel Angel / Roa Franco, Silvia / Navarro Jiménez, Gema / Moreno Palanco, Miguel Angel / González-Ruano, Patricia / López-Menchaca, Ramiro / Ruíz-Seco, Pilar / Pagán Muñoz, Bárbara / Gómez Gómez, Alejandro / Pérez-Monte, Beatriz / Fuerte Martínez, Rebeca / Valle López, Jose Luis / Muñoz Blanco, Arturo / Rábago Lorite, Isabel / Martínez Martín, Patricia / Serralta San Martín, Gonzalo /

Gómez-Cerezo, Jorge Francisco

Medicina clinica (English ed.)

2021 Volume 156, Issue 5, Page(s) 221–228

Abstract: Background: Several studies have reported the beneficial effect of glucocorticoids in the treatment of cytokine storm that occurs in patients with severe COVID-19. Various glucocorticoids regimens have been proposed.: Methods: Retrospective ... ...

Abstract	Background: Several studies have reported the beneficial effect of glucocorticoids in the treatment of cytokine storm that occurs in patients with severe COVID-19. Various glucocorticoids regimens have been proposed. Methods: Retrospective observational study that includes patients with severe SARS-CoV-2 pneumonia and compares admission to an Intensive Care Unit (ICU) or death during hospitalization in three groups of patients: no glucocorticoids treatment, use of glucocorticoids doses equivalent to less than 250 mg of prednisone daily and use of equivalent doses greater than or equal to 250 mg of prednisone daily. Multivariate analysis was performed using logistic regression, using the propensity index as a covariant. Results: Of the 259 patients enrolled in the study, 67 (25.9%) had an unfavorable evolution, dying or requiring ICU admission. Comparative analyzes between different glucocorticoids treatments and the association with ICU admission or death were: glucocorticoids treatment (any dose) versus no glucocorticoids treatment (OR: 0.71 [0.30-1.66]), treatment with glucocorticoids (≥250 mg prednisone daily) versus no glucocorticoids treatment (OR: 0.35 [0.11-1.08]) and glucocorticoids treatment (≥250 mg prednisone daily) versus patients with glucocorticoids doses <250 mg prednisone daily or without glucocorticoids treatment (OR: 0.30 [0.10-0.88]). Conclusion: The results of this study show that patients with severe SARS-CoV-2 pneumonia treated with glucocorticoids pulses with equivalent doses of prednisone greater than or equal to 250 mg have a more favorable evolution (less mortality and less admission to ICU).
Language	English
Publishing date	2021-02-06
Publishing country	Spain
Document type	Journal Article
ISSN	2387-0206
ISSN (online)	2387-0206
DOI	10.1016/j.medcle.2020.11.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014).

Ramírez-Lapausa, Marta / Pascual Pareja, José Francisco / Carrillo Gómez, Raquel / Martínez-Prieto, Mónica / González-Ruano Pérez, Patricia / Noguerado Asensio, Arturo

Enfermedades infecciosas y microbiologia clinica

2016 Volume 34, Issue 2, Page(s) 85–90

Abstract: Introduction: Although linezolid is known to be effective when used as an adjunct therapy in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB), the clinical experience is limited. In this study the efficacy and adverse effects of ... ...

Abstract	Introduction: Although linezolid is known to be effective when used as an adjunct therapy in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB), the clinical experience is limited. In this study the efficacy and adverse effects of linezolid treatment were evaluated. Methods: A retrospective study of tolerability and efficacy of linezolid in MDR-TB patients was performed in Madrid, Spain. Demographic characteristics, microbiological and clinical features and data on treatment tolerability were collected. Regimens were constructed with a target of prescribing, at least, five anti-tuberculosis agents likely to be effective. Linezolid, at a dosage of 1200 or 600 mg daily, was included to complete the treatment if no other sensitive drugs were available. Vitamin B6 was used to reduce toxicity. Treatment outcome and clinical status at last contact were compared between patients with linezolid-containing regimens and with those without linezolid-containing regimens. Results: During the period 1998-2014, 55 patients with MDR-TB received treatment. In 21 of these patients, linezolid was added. The median of linezolid administration was 23.9 months (IQT 13.1-24.7). Patients using linezolid showed a greater resistance to drugs, with a median of 6 (IQR 5-7) compared with those who did not use it, with a median of 4 drugs (IQR 3-5) (p<0.001). The median time to sputum culture conversion of the patients in the linezolid group (73.5 days) did not differ significantly from those in the non-linezolid group (61 days) (p=0.29). There were no significant differences in the outcomes of the two patient groups. There were no reported adverse events in 81% of patients assigned to linezolid therapy. Only four patients developed toxicity attributed to linezolid. The most serious adverse event in these patients was anemia observed in the two patients treated with 1200 mg per day. One of them also developed moderate paresthesia. In both cases the dosage was reduced to 600 mg per day, with improvement of the anemia and paresthesias. No patients stopped linezolid therapy. Conclusion: A daily dosage of 600 mg of linezolid was well tolerated without stopping treatment in any case. The efficacy of the treatment and the outcomes were similar in both the linezolid and non-linezolid group.
MeSH term(s)	Adult ; Antitubercular Agents/therapeutic use ; Female ; Humans ; Linezolid/therapeutic use ; Male ; Retrospective Studies ; Spain ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy
Chemical Substances	Antitubercular Agents ; Linezolid (ISQ9I6J12J)
Language	English
Publishing date	2016-02
Publishing country	Spain
Document type	Journal Article
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/j.eimc.2015.04.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Undetectable serum calcidiol: not everything that glitters is gold.

Gallegos-Bayas, Gioconda / Pascual-Pareja, José Francisco / Sanchez-Niño, Maria D / Manzarbeitia, Felix / Ortiz, Alberto

Clinical kidney journal

2012 Volume 5, Issue 1, Page(s) 37–40

Abstract: There is an increased awareness of the adverse consequences of nutritional vitamin D deficiency. We report a patient with chronic tophaceous gout, chronic kidney disease (CKD) Stage 3/4 and undetectable serum calcidiol who developed severe hypercalcaemia ...

Abstract	There is an increased awareness of the adverse consequences of nutritional vitamin D deficiency. We report a patient with chronic tophaceous gout, chronic kidney disease (CKD) Stage 3/4 and undetectable serum calcidiol who developed severe hypercalcaemia upon vitamin D supplementation despite serum 25(OH) vitamin D within the normal range. Upon recovery, serum 1,25(OH)2 vitamin D remained in the normal range despite CKD and serum 25(OH) vitamin D 6 ng/mL. Gout tophi biopsies from additional patients showed macrophage expression of 25(OH) vitamin D 1α-hydroxylase. This case illustrates the dangers of supplementing vitamin D in patients with low serum 25(OH) vitamin D and increased 1α-hydroxylase activity due to granulomatous disease.
Language	English
Publishing date	2012-01-28
Publishing country	England
Document type	Case Reports
ZDB-ID	2655800-2
ISSN	2048-8513 ; 2048-8505
ISSN (online)	2048-8513
ISSN	2048-8505
DOI	10.1093/ndtplus/sfr121
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6587: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2.

Gómez-Cerezo, Jorge Francisco

Medicina clinica

2020 Volume 156, Issue 5, Page(s) 221–228

Abstract: Introduction: Several studies have reported the beneficial effect of glucocorticoids in the treatment of cytokine storm that occurs in patients with severe COVID-19. Various glucocorticoids regimens have been proposed.: Methods: Retrospective ... ...

Title translation	Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.
Abstract	Introduction: Several studies have reported the beneficial effect of glucocorticoids in the treatment of cytokine storm that occurs in patients with severe COVID-19. Various glucocorticoids regimens have been proposed. Methods: Retrospective observational study that includes patients with severe SARS-CoV-2 pneumonia and compares admission to an Intensive Care Unit (ICU) or death during hospitalization in three groups of patients: no glucocorticoids treatment, use of glucocorticoids doses equivalent to less than 250mg of prednisone daily and use of equivalent doses greater than or equal to 250mg of prednisone daily. Multivariate analysis was performed using logistic regression, using the propensity index as a covariant. Results: Of the 259 patients enrolled in the study, 67 (25.9%) had an unfavorable evolution, dying or requiring ICU admission. Comparative analyzes between different glucocorticoids treatments and the association with ICU admission or death were: glucocorticoids treatment (any dose) versus no glucocorticoids treatment (OR: 0.71 [0.30-1.66]), treatment with glucocorticoids (≥250mg prednisone daily) versus no glucocorticoids treatment (OR: 0.35 [0.11-1.08]) and glucocorticoids treatment (≥250mg prednisone daily) versus patients with glucocorticoids doses <250mg prednisone daily or without glucocorticoids treatment (OR: 0.30 [0.10-0.88]). Conclusion: The results of this study show that patients with severe SARS-CoV-2 pneumonia treated with glucocorticoids pulses with equivalent doses of prednisone greater than or equal to 250mg have a more favorable evolution (less mortality and less admission to ICU).
MeSH term(s)	Adolescent ; Adult ; Aged ; Anti-Inflammatory Agents/therapeutic use ; COVID-19/complications ; COVID-19/mortality ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Glucocorticoids/therapeutic use ; Hospitalization ; Humans ; Logistic Models ; Male ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Young Adult ; COVID-19 Drug Treatment
Chemical Substances	Anti-Inflammatory Agents ; Glucocorticoids
Language	Spanish
Publishing date	2020-12-05
Publishing country	Spain
Document type	Journal Article ; Observational Study
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1016/j.medcli.2020.11.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain.

Moraleda, Cinta / Serna-Pascual, Miquel / Soriano-Arandes, Antoni / Simó, Silvia / Epalza, Cristina / Santos, Mar / Grasa, Carlos / Rodríguez, Maria / Soto, Beatriz / Gallego, Nerea / Ruiz, Yolanda / Urretavizcaya-Martínez, María / Pareja, Marta / Sanz-Santaeufemia, Francisco José / Fumadó, Victoria / Lanaspa, Miguel / Jordan, Iolanda / Prieto, Luis / Belda, Sylvia /

Toral-Vázquez, Belén / Rincón, Elena / Gil-Villanueva, Nuria / Méndez-Echevarría, Ana / Castillo-Serrano, Ana / Rivière, Jacques G / Soler-Palacín, Pere / Rojo, Pablo / Tagarro, Alfredo

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2020 Volume 72, Issue 9, Page(s) e397–e401

Abstract: Some clusters of children with a multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported. We describe the epidemiological and clinical features of children with ... ...

Abstract	Some clusters of children with a multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported. We describe the epidemiological and clinical features of children with MIS-C in Spain. MIS-C is a potentially severe condition that presents in children with recent SARS-CoV-2 infection.
MeSH term(s)	COVID-19 ; Child ; Humans ; SARS-CoV-2 ; Spain/epidemiology ; Syndrome ; Systemic Inflammatory Response Syndrome
Keywords	covid19
Language	English
Publishing date	2020-07-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciaa1042
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Thirty-day outcomes in frail older patients discharged home from the emergency department with acute heart failure: effects of high-risk criteria identified by the DEED FRAIL-AHF trial.

Martín-Sánchez, Francisco Javier / Parra Esquivel, Patricia / Llopis García, Guillermo / González Del Castillo, Juan / Rodríguez Adrada, Esther / Espinosa, Begoña / López Díez, María Pilar / Romero Pareja, Rodolfo / Rizzi Bordigoni, Miguel Alberto / Pérez-Durá, María José / Bibiano, Carlos / Ferrer, Carles / Aguiló, Sira / Martín Mojarro, Enrique / Aguirre, Alfons / Piñera, Pascual / López-Picado, Amanda / Llorens, Pere / Jacob, Javier /

Gil, Víctor / Herrero, Pablo / Fernández Pérez, Cristina / Gil, Pedro / Calvo, Elpidio / Rosselló, Xavier / Bueno, Héctor / Burillo, Guillermo / Miró, Òscar

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias

2021 Volume 33, Issue 3, Page(s) 165–173

Abstract: Objectives: To study the effect of high-risk criteria on 30-day outcomes in frail older patients with acute heart failure (AHF) discharged from an emergency department (ED) or an ED's observation and short-stay areas.: Material and methods: Secondary ...

Title translation	Resultados a 30 días en los pacientes mayores frágiles con insuficiencia cardiaca aguda dados de alta desde urgencias o sus unidades vinculadas que cumplen los criterios de alto riesgo del estudio DEED FRAIL-AHF.
Abstract	Objectives: To study the effect of high-risk criteria on 30-day outcomes in frail older patients with acute heart failure (AHF) discharged from an emergency department (ED) or an ED's observation and short-stay areas. Material and methods: Secondary analysis of discharge records in the Older AHF Key Data registry. We selected frail patients (aged > 70 years) discharged with AHF from EDs. Risk factors were categorized as modifiable or nonmodifiable. The outcomes were a composite endpoint for a cardiovascular event (revisits for AHF, hospitalization for AHF, or cardiovascular death) and the number of days alive out-of-hospital (DAOH) within 30 days of discharge. Results: We included 380 patients with a mean (SD) age of 86 (5.5) years (61.2% women). Modifiable risk factors were identified in 65.1%, nonmodifiable ones in 47.8%, and both types in 81.6%. The 30-day cardiovascular composite endpoint occurred in 83 patients (21.8%). The mean 30-day DAOH observed was 27.6 (6.1) days. Highrisk factors were present more often in patients who developed the cardiovascular event composite endpoint: the rates for patients with modifiable, nonmodifiable, or both types of risk were, respectively, as follows in comparison with patients not at high risk: 25.0% vs 17.2%, P = .092; 27.6% vs 16.7%, P = .010; and 24.7% vs 15.2%, P = .098). The 30-day DAOH outcome was also lower for at-risk patients, according to type of risk factor present: modifiable, 26.9 (7.0) vs 28.4 (4.4) days, P = .011; nonmodifiable, 27.1 (7.0) vs 28.0 (5.0) days, P = .127; and both, 27.1 (6.7) vs 28.8 (3.4) days, P = .005). After multivariate analysis, modifiable risk remained independently associated with fewer days alive (adjusted absolute difference in 30-day DAOH, -1.3 days (95% CI, -2.7 to -0.1 days). Nonmodifiable factors were associated with increased risk for the 30-day cardiovascular composite endpoint (adjusted absolute difference, 10.4%; 95% CI, -2.1% to 18.7%). Conclusion: Risk factors are common in frail elderly patients with AHF discharged home from hospital ED areas. Their presence is associated with a worse 30-day prognosis.
MeSH term(s)	Acute Disease ; Aged ; Aged, 80 and over ; Emergency Service, Hospital ; Female ; Frail Elderly ; Heart Failure/epidemiology ; Humans ; Male ; Patient Discharge
Language	Spanish
Publishing date	2021-05-30
Publishing country	Spain
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2127173-2
ISSN	2386-5857 ; 2386-5857
ISSN (online)	2386-5857
ISSN	2386-5857
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Bayesian Model to Predict COVID-19 Severity in Children.

Domínguez-Rodríguez, Sara / Villaverde, Serena / Sanz-Santaeufemia, Francisco J / Grasa, Carlos / Soriano-Arandes, Antoni / Saavedra-Lozano, Jesús / Fumadó, Victoria / Epalza, Cristina / Serna-Pascual, Miquel / Alonso-Cadenas, José A / Rodríguez-Molino, Paula / Pujol-Morro, Joan / Aguilera-Alonso, David / Simó, Silvia / Villanueva-Medina, Sara / Iglesias-Bouzas, M Isabel / Mellado, M José / Herrero, Blanca / Melendo, Susana /

De la Torre, Mercedes / Del Rosal, Teresa / Soler-Palacin, Pere / Calvo, Cristina / Urretavizcaya-Martínez, María / Pareja, Marta / Ara-Montojo, Fátima / Ruiz Del Prado, Yolanda / Gallego, Nerea / Illán Ramos, Marta / Cobos, Elena / Tagarro, Alfredo / Moraleda, Cinta

The Pediatric infectious disease journal

2021 Volume 40, Issue 8, Page(s) e287–e293

Abstract: Background: We aimed to identify risk factors causing critical disease in hospitalized children with COVID-19 and to build a predictive model to anticipate the probability of need for critical care.: Methods: We conducted a multicenter, prospective ... ...

Abstract	Background: We aimed to identify risk factors causing critical disease in hospitalized children with COVID-19 and to build a predictive model to anticipate the probability of need for critical care. Methods: We conducted a multicenter, prospective study of children with SARS-CoV-2 infection in 52 Spanish hospitals. The primary outcome was the need for critical care. We used a multivariable Bayesian model to estimate the probability of needing critical care. Results: The study enrolled 350 children from March 12, 2020, to July 1, 2020: 292 (83.4%) and 214 (73.7%) were considered to have relevant COVID-19, of whom 24.2% required critical care. Four major clinical syndromes of decreasing severity were identified: multi-inflammatory syndrome (MIS-C) (17.3%), bronchopulmonary (51.4%), gastrointestinal (11.6%), and mild syndrome (19.6%). Main risk factors were high C-reactive protein and creatinine concentration, lymphopenia, low platelets, anemia, tachycardia, age, neutrophilia, leukocytosis, and low oxygen saturation. These risk factors increased the risk of critical disease depending on the syndrome: the more severe the syndrome, the more risk the factors conferred. Based on our findings, we developed an online risk prediction tool (https://rserver.h12o.es/pediatria/EPICOAPP/, username: user, password: 0000). Conclusions: Risk factors for severe COVID-19 include inflammation, cytopenia, age, comorbidities, and organ dysfunction. The more severe the syndrome, the more the risk factor increases the risk of critical illness. Risk of severe disease can be predicted with a Bayesian model.
MeSH term(s)	Adolescent ; Bayes Theorem ; COVID-19/diagnosis ; COVID-19/epidemiology ; Child ; Child, Preschool ; Comorbidity ; Critical Care ; Critical Illness ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Prospective Studies ; Risk Factors ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Systemic Inflammatory Response Syndrome/diagnosis ; Systemic Inflammatory Response Syndrome/epidemiology
Language	English
Publishing date	2021-07-07
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	392481-6
ISSN	1532-0987 ; 0891-3668
ISSN (online)	1532-0987
ISSN	0891-3668
DOI	10.1097/INF.0000000000003204
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1852: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito